CoChat

A double-blind, placebo-controlled trial of clonazepam in obsessive–compulsive disorder

Hollander, Eric, Kaplan, Alicia, Stahl, Stephen M · 2003 · The World Journal of Biological Psychiatry

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are currently the first-line pharmacological agents in treating obsessive-compulsive disorder (OCD). Appropriate treatment for OCD also involves cognitive behavioural therapy (CBT), including exposure and response prevention. As there is a time delay in seeing full therapeutic response, and not all patients tolerate SSRIs, there remains an unmet need for additional treatment approaches in OCD. In addition, most responders report only a partial reduction in symptoms. Clonazepam has demonstrated effectiveness in several preliminary reports in treating OCD. Twenty-seven patients with OCD were entered into a 10 week, double-blind, parallel design trial of clonazepam vs. placebo. Overall, only 3 out of 25 patients who had >/= 1 rating on clonazepam/placebo were judged to be treatment responders, by scoring a 1 (very much improved) or 2 (much improved) on the CGI improvement scale. Responders included 2 of 9 in the placebo group and 1 of 16 in the clonazepam group. No significant difference was found between clonazepam and placebo groups on responder/non responder status (Chi(2 )=1.39, df =1,24, p=0.238), nor on change in YBOCS, Ham-A, Ham-D or NIMH scales from beginning to last evaluation carried forward. These findings suggest that clonazepam is not effective as monotherapy in treating OCD. Its effectiveness in specific subgroups of OCD patients with co-morbid anxiety disorders or as an augmentation strategy added to SSRIs remains to be determined.

Overview

Integrity signals

Registry

Crossref · 10.3109/15622970309167908

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Research works printed but not linked: 7

  1. Bacher N H, 1990, J Clin Psychiatry, 51, 168
  2. Bodkin J A, 1989, J Clin Psychiatry, 50, 265
  3. Davidson J R, 1998, Psychopharmacol Bull, 34, 169
  4. Hewlett W A, 1990, J Clin Psychiatry, 51, 158
  5. Ross D C, 1993, J Am Acad Child Adoles Psychiatry, 32, 470
  6. Wagner H R, 1986, Adv Neurol, 43, 645
  7. Weissman M M, 1994, J Clin Psychiatry, 55, 5

Cited by

See all 97

Metadata

Authors
Hollander, E., Kaplan, A., & Stahl, S. M.
Affiliations
  • Icahn School of Medicine at Mount Sinai (US)
  • University of California San Diego (US)
Corresponding author
Hollander, Eric
Venue
The World Journal of Biological Psychiatry
Published
2003-01
Volume
4
Issue
1
Pages
30-34
ISSN
  • 1562-2975 (ISSN-L)
  • 1814-1412
OpenAlex
W2050637887
Cited by
97
References
23
Citations by year
2026: 1 · 2024: 4 · 2023: 3 · 2022: 1 · 2021: 4 · 2020: 3 · 2018: 6 · 2017: 5 · 2016: 3 · 2015: 9 · 2014: 3 · 2013: 5 · 2012: 9
FWCI
8.54
Type
journal article
Language
en
Open access
closed
Locations
  • The World Journal of Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Georgetown University
  • University of California, San Diego
  • School of Medicine, University of California, San Diego
Topics
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
Keywords
clonazepam, obsessive-compulsive disorder, benzodiazepines, treatment response, monotherapy, selective serotonin reuptake inhibitors, augmentation therapy, anxiety comorbidity
MeSH terms
Adult, Aged, Anticonvulsants, Clonazepam, Double-Blind Method, Female, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Severity of Illness Index, Cognitive Behavioral Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A double-blind, placebo-controlled trial of clonazepam in obsessive–compulsive disorder. https://app.cochat.ai/papers/10.3109/15622970309167908
The paper
Hollander, E., Kaplan, A., & Stahl, S. M. (2003). A double-blind, placebo-controlled trial of clonazepam in obsessive–compulsive disorder. The World Journal of Biological Psychiatry. https://doi.org/10.3109/15622970309167908

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.